[Vaccination against pneumococcal and influenza infections in children and adolescents with type 1 diabetes].

The effect of a Pneumo 23 vaccine against pneumococcal infection (n = 72; Subgroup 1) in combination with a Grippol vaccine against influenza infection (n = 28; Subgroup 2) was studied in children and adolescents with type 1 diabetes on insulin therapy. A control group consisted of 30 unvaccinated children. Unlike monovaccination, combined vaccination was ascertained to cause a significant reduction in the glycated hemoglobin following a year.

[The level of antibodies to pneumococcal vaccine in children and adolescents with type 1 diabetes].

The trend in the formation of postvaccinal antibodies (Ab) to a mixture of S. pneumoniae polysaccharides (PS) was studied in 100 Pneumo 23-vaccinated children and adolescents with type 1 diabetic (T1D) (Group 1, n = 72) and its combination with the subunit vaccine Grippol (Group 2, n = 28). Following 1-1.

[Autoantibodies after vaccination against pneumococcal and influenza infections in children and adolescents with type I diabetes mellitus].

Aim: To study the influence of vaccination against pneumococcal and influenza infections on the levels of autoantibodies to DNA, pancreatic and adrenal tissues as well as on populations of lymphocytes and levels of immunoglobulins in children and adolescents with type I diabetes mellitus (DM1).

Materials And Methods: One hundred and thirty children and adolescents 2 - 18 years of age were followed during 12 months. One hundred participants were vaccinated against pneumococcal infection with Pneumo 23 vaccine.

[Immunity to measles after vaccination of children with rheumatic diseases].

Medical history, immunization status were studied and serologic tests were performed in 72 children aged 1-16 years (mean age 10.8 +/- 0.49 years) with rheumatic diseases (juvenile rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, Overlap-syndrome, etc.

[Assessment of effect of vaccination against pneumococcal infection in children with chronic renal failure and glomerulonephritis].

Clinical effect and immune response to vaccination with PNEUMO 23 vaccine was assessed in 18 children with chronic renal failure (CRF) and 40 children with different forms of glomerulonephritis (GN) aged 2 - 15 years. Control group was comprised by nonvaccinated patients (16 patients with CRF; 20 -with GN). Children from two groups were comparable on age and severity of disease's course.